A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

Trial Profile

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs SRP 4045 (Primary) ; SRP 4053 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms ESSENCE
  • Sponsors Sarepta Therapeutics
  • Most Recent Events

    • 28 Sep 2016 According to a Sarepta Therapeutics media release, the first patient dosed in September 2016.
    • 01 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 16 Jun 2016 Planned End Date changed from 1 May 2018 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top